TABLE 3.
Total Costs over 2 Years Without Rebate
| Treatment Sequence Excluding Tofacitinib | Tofacitinib Comparator Sequence 1 | Tofacitinib Comparator Sequence 2 | Tofacitinib Comparator Sequence 3 | |
|---|---|---|---|---|
| Treatment sequence | ADA→ETA→APR→SEC | TOF→ADA→ETA→APR | ADA→TOF→ETA→APR | APR→TOF→ADA→SEC |
| Total costs, $ | 36,449,210 | 31,225,220 | 34,419,371 | 27,994,352 |
| Total costs PMPM, $ | 1.52 | 1.30 | 1.43 | 1.17 |
| Total ACR20 responders | 252 | 261 | 261 | 253 |
| Total costs per ACR20 responder, $ | 144,376 | 119,706 | 132,040 | 110,683 |
| Total ACR50 responders | 169 | 171 | 174 | 141 |
| Total costs per ACR50 responder, $ | 215,900 | 182,806 | 198,351 | 198,462 |
| Total ACR70 responders | 81 | 81 | 94 | 72 |
| Total costs per ACR70 responder, $ | 449,473 | 383,946 | 368,076 | 388,119 |
| Cost type, $ | ||||
| Drug acquisition | 35,777,297 | 30,516,914 | 33,762,831 | 27,215,006 |
| Administration | 407,956 | 377,332 | 393,876 | 393,781 |
| Monitoring | 173,495 | 291,723 | 214,204 | 323,808 |
| ADR | 90,463 | 39,251 | 48,460 | 61,757 |
ACR20/50/70 = American College of Rheumatology response criteria of 20/50/70%; ADA = adalimumab; ADR = adverse drug reaction; APR = apremilast; ETA = etanercept; PMPM = per member per month; SEC = secukinumab; TOF = tofacitinib.